• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Patient Care Falters as COVID-19 Devastates L.A. County (CA) Hospitals
Soumya Karlamangla, Rong-Gong Lin II, Luke Money Los Angeles Times (MCT) Los Angeles County’s healthcare system was buckling Wednesday under the unprecedented surge of COVID-19 patients, with bodies piling up at morgues and medical professionals resorting to increasingly desperate measures as they brace for conditions to worsen in the coming weeks. With hospitals overwhelmed by patients and no outlet valve available, doctors, nurses and paramedics are being forced to make wrenching choices about who gets care and at what level. “No one would believe this is in the United States,” ...
Source: JEMS Patient Care - December 31, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus News News Feed California EMS Hospital Paramedic Source Type: news

COVID-19 Exposed the Faults in America ’s Elder Care System. This Is Our Best Shot to Fix Them
For the American public, one of the first signs of the COVID-19 pandemic to come was a tragedy at a nursing home near Seattle. On Feb. 29, 2020, officials from the U.S. Centers for Disease Control and Prevention (CDC) and Washington State announced the U.S. had its first outbreak of the novel coronavirus. Three people in the area had tested positive the day before; two of them were associated with Life Care Center of Kirkland, and officials expected more to follow soon. When asked what steps the nursing home could take to control the spread, Dr. Jeff Duchin, health officer for Seattle and King County, said he was working w...
Source: TIME: Health - June 15, 2021 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Aging COVID-19 feature franchise Magazine TIME for Health Source Type: news

For HIV/AIDS Survivors, COVID-19 Reawakened Old Trauma —And Renewed Calls for Change
Forty years ago this month, the U.S. Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report noted a rare lung infection among five otherwise healthy gay men in Los Angeles, Calif. Though they didn’t know it at the time, the scientists had written about what would turn out to be one of the historical moments that launched the Acquired Immunodeficiency Syndrome (AIDS) epidemic. Since then, HIV/AIDS has killed an estimated 35 million people, including 534,000 people in the U.S. from 1990 to 2018 alone, according to UNAIDS, making it one of the deadliest epidemics in modern history. Over...
Source: TIME: Health - June 17, 2021 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 Source Type: news

Pediatric COVID-19 Cases Are Surging, Pushing Hospitals —and Health Care Workers—to Their Breaking Points
Aug. 20 was a good day in the pediatric intensive care unit at Children’s Hospital New Orleans. Carvase Perrilloux, a two-month-old baby who’d come in about a week earlier with respiratory syncytial virus and COVID-19, was finally ready to breathe without the ventilator keeping his tiny body alive. “You did it!” nurses in PPE cooed as they removed the tube from his airway and he took his first solo gasp, bare toes kicking. Downstairs, Quintetta Edwards was preparing for her 17-year-old son, Nelson Alexis III, to be discharged after spending more than two weeks in the hospital with COVID-19—fir...
Source: TIME: Health - August 26, 2021 Category: Consumer Health News Authors: Jamie Ducharme/New Orleans, La. Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Emergency Medical Service Workers Battle a Hurricane, and COVID-19, To Bring Health Care To New Orleans
As Hurricane Ida pounded the coast of New Orleans with downpours and 150-mile-per-hour winds on the afternoon of Aug. 29, New Orleans Emergency Medical Services had to reverse course after spending 18 months running around the city at full speed battling COVID-19: staying put. For 13 hours and 41 minutes, as the storm’s worst shook their community, the workers hunkered down at their base, keeping themselves safe to be ready to protect others from whatever came next. However, the deluge of 9-1-1 calls didn’t come to a halt as EMS waited out the storm. So, after EMS workers were given the go-ahead to rush back in...
Source: TIME: Health - September 7, 2021 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized climate change COVID-19 healthscienceclimate Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

These Charts Show That COVID-19 is Still the Pandemic of the Unvaccinated
Over the summer of 2021, as the Delta variant swept the nation, Americans’ experience with COVID-19 bifurcated. Among vaccinated people, cases were low and deaths were rare; at the same time, people with no immunity were getting sick and dying at alarming rates. COVID-19 became the pandemic of the unvaccinated. Then in December, Omicron showed up. Cases have surged in recent weeks, blowing past records set during the Delta wave. Driving this trend is Omicron’s extremely high transmissibility, compounded by waning immunity among vaccinated people who are experiencing symptomatic breakthrough infections. With cas...
Source: TIME: Health - January 12, 2022 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Safety of SARS-CoV-2 vaccination in patients with Behcet ’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine
AbstractMost of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Beh çet’s syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducte d using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by a single university hospital. Study participants were vaccinated either with C...
Source: Rheumatology International - April 4, 2022 Category: Rheumatology Source Type: research

Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine
Rheumatol Int. 2022 Apr 4. doi: 10.1007/s00296-022-05119-y. Online ahead of print.ABSTRACTMost of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet's syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducted using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by ...
Source: Pain Physician - April 4, 2022 Category: Anesthesiology Authors: Ayse Ozdede Sabriye Guner Guzin Ozcifci Berna Yurttas Zeynep Toker Dincer Zeynep Atli U ğur Uygunoğlu Eser Durmaz Didar U çar Serdal U ğurlu Sabahattin Saip Fehmi Tabak Vedat Hamuryudan Emire Seyahi Source Type: research

Pages: 1  2  3  4  5  6